LambdaVision
a pre-clinical-stage biotech manufacturing protein-based artificial retinas using microgravity's layer-deposition advantages, expanding its commercial low-Earth-orbit manufacturing strategy from the ISS to commercial space stations under a new agreement.
- Country
- United States
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| upstream-bioreactors | ✓ | ✓ | ✓ |
Regulatorsfdafaa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Space bioeconomy | upstream-bioreactors | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.